Actively Recruiting
The Clinical Efficacy of Immunomodulators in RA Patients
Led by Qilu Hospital of Shandong University · Updated on 2022-11-29
400
Participants Needed
1
Research Sites
262 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study includes naive patients and csDMARDs-IR RA patients, treated with different regimens such as Iguratimod combination of different csDMARDs, or csDMARD with TNF inhibitors for 24 weeks. The disease activity and drug response will be observed. The immune disorder and synovial function will be evaluated at the same time.
CONDITIONS
Official Title
The Clinical Efficacy of Immunomodulators in RA Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with rheumatoid arthritis meeting ACR 1987 or ACR/EULAR 2010 classification criteria and having knee dysfunction
- Patients with osteoarthritis meeting 1995 classification criteria for knee osteoarthritis and having knee dysfunction
- Age over 18 years
- Voluntary participation with signed informed consent
- Healthy volunteers matched by age and sex for control group
You will not qualify if you...
- Patients with active hepatitis
- Patients with active tuberculosis
- Patients with infection or malignancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qilu Hospital
Jinan, Shandong, China, 250012
Actively Recruiting
Research Team
Q
Qiang Shu, Dr.
CONTACT
B
Bingbing Ren
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here